NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Geron Corporation (“Geron” or the “Company”) (GERN). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 9980.
The investigation concerns whether Geron and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On September 27, 2018, Geron issued a press release disclosing disappointing results in the Company’s IMbark study of imetelstat, its intended bone marrow cancer treatment. Specifically, Geron disclosed that patients in the IMbark study had shown only 10% spleen volume reduction and 32% TSS reduction, both of which metrics fell well short of the study’s primary endpoints required for success. Concurrently, Geron disclosed the termination of its partnership with Janssen Biotech Inc. for the development of Imetelstat.
On this news, Geron’s stock price fell $3.92 per share, or 62.92%, to close at $2.31 per share on September 27, 2018.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
Robert S. Willoughby